Evidence map›Paper›PMID 26304941›Full record

Trial reportJournal of the American Heart Association2015

Colchicine Acutely Suppresses Local Cardiac Production of Inflammatory Cytokines in Patients With an Acute Coronary Syndrome.

Gonzalo J Martínez, Stacy Robertson, Jennifer Barraclough, Qiong Xia, Ziad Mallat, Christina Bursill, David S Celermajer, Sanjay Patel

3 registry-linked trialsOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American Heart Association, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 126 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
126citing papers in PubMed, 5 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04218786 phase2withdrawnnot on this mapstarted 2025, after this paper: background citation

Outcomes of Low-dose Colchicine in Patients With Myocardial Infarction: A Randomized Controlled Trial

TypeinterventionalSponsorShifa Tameer-e-Millat UniversityRan2025 to 2026Enrolled0ConditionsMyocardium, Injury, Myocardial Infarction, Myocardial IschemiaArmsColchicine, Placebo oral tablet
NCT05734612 phase3unknown statusnot on this mapstarted 2022, after this paper: background citation

The Role of Colchicine in Reducing The Rate of Myocardial Reperfusion Injury in Patients With ST-Elevation Myocardial Infarction After Primary Percutaneous Coronary Intervention: Study on NLRP3, ASC, Caspase, and Troponin

TypeinterventionalSponsorIndonesia UniversityRan2022 to 2023Enrolled80ConditionsReperfusion Injury, MyocardialArmsColchicine, Placebo (lactose)
NCT06936709 phase4not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Effect of Colchicine in the Perioperative Period on Reducing Post-Operative Pain in Total Knee Arthroplasty

TypeinterventionalSponsorGeisinger ClinicRan2025 to 2026Enrolled75ConditionsOsteoarthritis of Knee, Recovery Following Primary Total Knee Arthroplasty, Perioperative Pain ControlArmsColchicine 1.8 mg (loading dose) + Dextrose Oral Placebo, Colchicine 1.8 mg + 0.6 mg, Dextrose Oral Placebo
3 · Its place in the literature

Who cites it

126 citing papers in PubMed, 5 syntheses or guidelines pooled it, 277 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Review
  12. Colchicine initiated before radiofrequency-induced injury attenuates left atrial inflammation, fibrosis, and susceptibility to atrial fibrillation.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Article
  13. Low-Dose Colchicine for Secondary Prevention in Patients With Chronic Coronary Syndrome: A Multicenter Real-World Study.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2026
    Observational
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

66 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 4 countries.

Gonzalo J MartínezDepartment of Cardiology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia (G.J.M., J.B., D.S.C., S.P.) Sydney Medical School, The University of Sydney, New South Wales, Australia (G.J.M., S.R., Q.X., C.B., D.S.C., S.P.) Department of Cardiology, Catholic University School of Medicine, Santiago, Chile (G.J.M.).
Stacy RobertsonSydney Medical School, The University of Sydney, New South Wales, Australia (G.J.M., S.R., Q.X., C.B., D.S.C., S.P.) Heart Research Institute, Sydney, New South Wales, Australia (S.R., C.B., D.S.C., S.P.).
Jennifer BarracloughDepartment of Cardiology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia (G.J.M., J.B., D.S.C., S.P.).
Qiong XiaSydney Medical School, The University of Sydney, New South Wales, Australia (G.J.M., S.R., Q.X., C.B., D.S.C., S.P.).
Ziad MallatInstitut National de la Santé et de la Recherche Médicale (INSERM), Paris-Cardiovascular Research Center, Paris, France (Z.M.) Division of Cardiovascular Medicine, Addenbrooke's Hospital, University of Cambridge, United Kingdom (Z.M.).
Christina BursillSydney Medical School, The University of Sydney, New South Wales, Australia (G.J.M., S.R., Q.X., C.B., D.S.C., S.P.) Heart Research Institute, Sydney, New South Wales, Australia (S.R., C.B., D.S.C., S.P.).
David S CelermajerDepartment of Cardiology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia (G.J.M., J.B., D.S.C., S.P.) Sydney Medical School, The University of Sydney, New South Wales, Australia (G.J.M., S.R., Q.X., C.B., D.S.C., S.P.) Heart Research Institute, Sydney, New South Wales, Australia (S.R., C.B., D.S.C., S.P.).
Sanjay PatelDepartment of Cardiology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia (G.J.M., J.B., D.S.C., S.P.) Sydney Medical School, The University of Sydney, New South Wales, Australia (G.J.M., S.R., Q.X., C.B., D.S.C., S.P.) Heart Research Institute, Sydney, New South Wales, Australia (S.R., C.B., D.S.C., S.P.).
University of Sydney · AUParis Cardiovascular Research Center · FRRoyal Prince Alfred Hospital · AUThe Heart Research Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInterleukin (IL)-1β, IL-18, and downstream IL-6 are key inflammatory cytokines in the pathogenesis of coronary artery disease. Colchicine is believed to block the NLRP3 inflammasome, a cytosolic complex responsible for the production of IL-1β and IL-18. In vivo effects of colchicine on cardiac cytokine release have not been previously studied. This study aimed to (1) assess the local cardiac production of inflammatory cytokines in patients with acute coronary syndromes (ACS), stable coronary artery disease and in controls; and (2) determine whether acute administration of colchicine inhibits their production. METHODS AND

resultsForty ACS patients, 33 with stable coronary artery disease, and 10 controls, were included. ACS and stable coronary artery disease patients were randomized to oral colchicine treatment (1 mg followed by 0.5 mg 1 hour later) or no colchicine, 6 to 24 hours prior to cardiac catheterization. Blood samples from the coronary sinus, aortic root (arterial), and lower right atrium (venous) were collected and tested for IL-1β, IL-18, and IL-6 using ELISA. In ACS patients, coronary sinus levels of IL-1β, IL-18, and IL-6 were significantly higher than arterial and venous levels (P=0.017, <0.001 and <0.001, respectively). Transcoronary (coronary sinus-arterial) gradients for IL-1β, IL-18, and IL-6 were highest in ACS patients and lowest in controls (P=0.077, 0.033, and 0.014, respectively). Colchicine administration significantly reduced transcoronary gradients of all 3 cytokines in ACS patients by 40% to 88% (P=0.028, 0.032, and 0.032, for IL-1β, IL-18, and IL-6, respectively).

conclusionsACS patients exhibit increased local cardiac production of inflammatory cytokines. Short-term colchicine administration rapidly and significantly reduces levels of these cytokines.

Indexed as

Acute Coronary SyndromeAgedAnti-Inflammatory AgentsBiomarkersColchicineCoronary Artery DiseaseCoronary SinusCytokinesDown-RegulationEnzyme-Linked Immunosorbent AssayFemaleHumansInflammation MediatorsInterleukin-18Interleukin-1betaInterleukin-6Anti-Inflammatory AgentsBiomarkersColchicineCytokinesIL1B protein, humanIL6 protein, humanInflammation MediatorsInterleukin-18Interleukin-1betaInterleukin-6atherosclerosiscoronary sinus samplingcytokinesinflammation

Identifiers

PMID26304941
PMCPMC4599469
OpenAlexW2128383347

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.